NASDAQ:NTLA Intellia Therapeutics (NTLA) Stock Price, News & Analysis → You won't believe what Citigroup just did to it's depositors (From American Alternative) (Ad) Free NTLA Stock Alerts $22.73 -0.22 (-0.96%) (As of 06/7/2024 08:52 PM ET) Add Compare Share Share Today's Range$22.43▼$23.1850-Day Range$20.02▼$27.2252-Week Range$19.37▼$47.48Volume1.45 million shsAverage Volume1.53 million shsMarket Capitalization$2.19 billionP/E RatioN/ADividend YieldN/APrice Target$66.77 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Intellia Therapeutics alerts: Email Address Intellia Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.69 Rating ScoreUpside/Downside193.7% Upside$66.77 Price TargetShort InterestBearish15.73% of Shares Sold ShortDividend StrengthN/ASustainability-0.67Upright™ Environmental ScoreNews Sentiment0.83Based on 17 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($5.00) to ($5.28) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.35 out of 5 starsMedical Sector261st out of 903 stocksDiagnostic Substances Industry4th out of 14 stocks 3.3 Analyst's Opinion Consensus RatingIntellia Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on 9 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageIntellia Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Intellia Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted15.73% of the outstanding shares of Intellia Therapeutics have been sold short.Short Interest Ratio / Days to CoverIntellia Therapeutics has a short interest ratio ("days to cover") of 10.7, which indicates bearish sentiment.Change versus previous monthShort interest in Intellia Therapeutics has recently decreased by 1.75%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldIntellia Therapeutics does not currently pay a dividend.Dividend GrowthIntellia Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIntellia Therapeutics has received a 74.63% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health", "Clinical research services for genetic diseases", and "Basic medical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Intellia Therapeutics is -0.67. Previous Next 2.7 News and Social Media Coverage News SentimentIntellia Therapeutics has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Intellia Therapeutics this week, compared to 4 articles on an average week.Search Interest19 people have searched for NTLA on MarketBeat in the last 30 days. This is an increase of 12% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Intellia Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -42% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Intellia Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.00% of the stock of Intellia Therapeutics is held by insiders.Percentage Held by Institutions88.77% of the stock of Intellia Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Intellia Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Intellia Therapeutics are expected to decrease in the coming year, from ($5.00) to ($5.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Intellia Therapeutics is -4.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Intellia Therapeutics is -4.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIntellia Therapeutics has a P/B Ratio of 1.94. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Intellia Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Smallcaps DailyIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promising companies to be watching closelyLearn how this American company is leading the lithium-ion revolution About Intellia Therapeutics Stock (NASDAQ:NTLA)Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Read More NTLA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NTLA Stock News HeadlinesJune 9 at 6:20 AM | fool.comCathie Wood Goes Bargain Hunting: 2 Stocks She Just BoughtJune 8 at 7:25 AM | fool.comThese 2 Words Are Why Intellia Therapeutics Could Be a Smart Buy Right NowJune 6, 2024 | fool.comCathie Wood Goes Bargain Hunting: 3 Stocks She Just BoughtJune 6, 2024 | americanbankingnews.comIntellia Therapeutics (NASDAQ:NTLA) Trading 2.4% Higher June 6, 2024 | americanbankingnews.comIntellia Therapeutics (NASDAQ:NTLA) Stock Rating Reaffirmed by Cantor FitzgeraldJune 5, 2024 | investorplace.comThe 3 Best Biotech Stocks to Buy in June 2024June 5, 2024 | seekingalpha.comIntellia Therapeutics Presents Promising In Vivo CRISPR ResultsJune 4, 2024 | fool.comCathie Wood Is Buying the Dip on These 2 Biotech Stocks. Should You?June 3, 2024 | insidermonkey.comIs Intellia Therapeutics, Inc. (NASDAQ:NTLA) the Most Promising Gene Therapy Stock to Buy Now?June 2, 2024 | globenewswire.comIntellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)June 1, 2024 | americanbankingnews.comIntellia Therapeutics, Inc. Expected to Post FY2024 Earnings of ($4.50) Per Share (NASDAQ:NTLA)May 22, 2024 | fool.comCathie Wood Goes Bargain Hunting: 3 Stocks She Just BoughtMay 14, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Aura Biosciences Inc (AURA), Iovance Biotherapeutics (IOVA) and Intellia Therapeutics (NTLA)May 13, 2024 | seekingalpha.comIntellia Therapeutics: 3 Near-Term Pivotal In Vivo Gene TherapiesMay 12, 2024 | finance.yahoo.comEarnings Beat: Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their ForecastsMay 10, 2024 | markets.businessinsider.comBarclays Reaffirms Their Buy Rating on Intellia Therapeutics (NTLA)May 10, 2024 | fool.comCathie Wood Goes Bargain Hunting: 3 Stocks She Just BoughtMay 10, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Tarsus Pharmaceuticals (TARS), Collegium Pharmaceutical (COLL) and Intellia Therapeutics (NTLA)May 10, 2024 | finance.yahoo.comIntellia Therapeutics First Quarter 2024 Earnings: Beats ExpectationsMay 9, 2024 | msn.comNTLA Stock Earnings: Intellia Therapeutics Beats EPS, Beats Revenue for Q1 2024May 9, 2024 | finanznachrichten.deIntellia Therapeutics, Inc.: Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company ProgressMay 9, 2024 | seekingalpha.comCrispr Therapeutics Q1 Earnings: Casgevy Launch Tip Of Gene Editing IcebergMay 9, 2024 | globenewswire.comIntellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company ProgressMay 3, 2024 | investorplace.comShhh! 3 Secret Gene Editing Stocks Flying Below Wall Street's RadarMay 3, 2024 | investing.comIntellia Therapeutics Inc (NTLA) Earnings Dates & ReportsSee More Headlines Receive NTLA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intellia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/10/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryN/A Current SymbolNASDAQ:NTLA CUSIPN/A CIK1652130 Webwww.intelliatx.com Phone(857) 285-6200FaxN/AEmployees526Year FoundedN/APrice Target and Rating Average Stock Price Target$66.77 High Stock Price Target$107.00 Low Stock Price Target$29.00 Potential Upside/Downside+193.7%Consensus RatingModerate Buy Rating Score (0-4)2.69 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($5.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-481,190,000.00 Net Margins-893.34% Pretax Margin-922.94% Return on Equity-45.35% Return on Assets-37.40% Debt Debt-to-Equity RatioN/A Current Ratio9.03 Quick Ratio9.03 Sales & Book Value Annual Sales$36.28 million Price / Sales60.44 Cash FlowN/A Price / Cash FlowN/A Book Value$11.73 per share Price / Book1.94Miscellaneous Outstanding Shares96,470,000Free Float93,581,000Market Cap$2.19 billion OptionableOptionable Beta1.84 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. John M. Leonard M.D. (Age 67)President, CEO & Director Comp: $1.06MMr. Glenn G. Goddard CPA (Age 53)Executive VP, CFO & Treasurer Comp: $630.91kDr. Laura Sepp-Lorenzino Ph.D. (Age 63)Executive VP & Chief Scientific Officer Comp: $670.58kMr. James E. Basta Esq. (Age 58)J.D., Executive VP, General Counsel & Corporate Secretary Comp: $616.15kDr. David Lebwohl M.D. (Age 69)Executive VP & Chief Medical Officer Comp: $671.42kMr. Derek Hicks (Age 50)Executive VP & Chief Business Officer Comp: $823.42kMr. Nessan Bermingham Ph.D. (Age 51)Founder & Member of Scientific Advisor Board Comp: $1.38MDr. Rachel E. Haurwitz Ph.D. (Age 38)Co-Founder Dr. Andrew May Ph.D.Founder and Member of Scientific Advisor BoardDr. Jennifer A. Doudna Ph.D. (Age 60)Founder & Member of Scientific Advisor Board More ExecutivesKey CompetitorsMeridian BioscienceNASDAQ:VIVOEditas MedicineNASDAQ:EDITCellectisNASDAQ:CLLSSangamo TherapeuticsNASDAQ:SGMOCRISPR TherapeuticsNASDAQ:CRSPView All CompetitorsInsiders & InstitutionsDekaBank Deutsche GirozentraleSold 3,129 shares on 6/4/2024Ownership: 0.078%Opaleye Management Inc.Bought 156,000 shares on 5/29/2024Ownership: 0.264%Virtu Financial LLCBought 29,144 shares on 5/20/2024Ownership: 0.030%Comerica BankBought 33,214 shares on 5/17/2024Ownership: 0.038%Walleye Trading LLCSold 8,700 shares on 5/17/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions NTLA Stock Analysis - Frequently Asked Questions Should I buy or sell Intellia Therapeutics stock right now? 13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last year. There are currently 4 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NTLA shares. View NTLA analyst ratings or view top-rated stocks. What is Intellia Therapeutics' stock price target for 2024? 13 analysts have issued twelve-month price objectives for Intellia Therapeutics' shares. Their NTLA share price targets range from $29.00 to $107.00. On average, they predict the company's stock price to reach $66.77 in the next twelve months. This suggests a possible upside of 193.7% from the stock's current price. View analysts price targets for NTLA or view top-rated stocks among Wall Street analysts. How have NTLA shares performed in 2024? Intellia Therapeutics' stock was trading at $30.49 at the beginning of the year. Since then, NTLA stock has decreased by 25.5% and is now trading at $22.73. View the best growth stocks for 2024 here. When is Intellia Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our NTLA earnings forecast. How were Intellia Therapeutics' earnings last quarter? Intellia Therapeutics, Inc. (NASDAQ:NTLA) announced its quarterly earnings results on Thursday, May, 9th. The company reported ($1.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.35) by $0.29. The firm had revenue of $28.94 million for the quarter, compared to analyst estimates of $15.60 million. Intellia Therapeutics had a negative trailing twelve-month return on equity of 45.35% and a negative net margin of 893.34%. What ETFs hold Intellia Therapeutics' stock? ETFs with the largest weight of Intellia Therapeutics (NASDAQ:NTLA) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), Global X Genomics & Biotechnology ETF (GNOM), Morningstar US Small Growth (MSGR), ARK Genomic Revolution ETF (ARKG), ARK Innovation ETF (ARKK), Tema Oncology ETF (CANC), Tema Cardiovascular and Metabolics ETF (HRTS) and Horizon Kinetics Medical ETF (MEDX). What is John Leonard, M.D.'s approval rating as Intellia Therapeutics' CEO? 12 employees have rated Intellia Therapeutics Chief Executive Officer John Leonard, M.D. on Glassdoor.com. John Leonard, M.D. has an approval rating of 73% among the company's employees. What other stocks do shareholders of Intellia Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Intellia Therapeutics investors own include Editas Medicine (EDIT), CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Micron Technology (MU), Advanced Micro Devices (AMD), Intel (INTC), Invitae (NVTA) and Cisco Systems (CSCO). When did Intellia Therapeutics IPO? Intellia Therapeutics (NTLA) raised $85 million in an initial public offering (IPO) on Friday, May 6th 2016. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Intellia Therapeutics' major shareholders? Intellia Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.43%), Sumitomo Mitsui Trust Holdings Inc. (3.52%), Nikko Asset Management Americas Inc. (3.52%), Price T Rowe Associates Inc. MD (1.68%), Chevy Chase Trust Holdings LLC (1.11%) and Pinnacle Associates Ltd. (0.27%). Insiders that own company stock include David Lebwohl, Eliana Clark, Glenn Goddard, James Basta, Jean Francois Formela, John F Crowley, John M Leonard, John M Leonard, Laura Sepp-Lorenzino and Muna Bhanji. View institutional ownership trends. How do I buy shares of Intellia Therapeutics? Shares of NTLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NTLA) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredYou won't believe what Citigroup just did to it's depositorsThe FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st...American Alternative | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intellia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intellia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.